News 25.03.2021 Zurich-Schlieren, Switzerland, March 25, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Dominik Höchli, M.D., to the Company’s Board of Directors proposed for election at the 2021 Annual General...
News 22.03.2021 Zurich-Schlieren, Switzerland, March 22, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares...
News 18.03.2021 Schlieren (Zurich), Switzerland, March 18, 2021 – Kuros Biosciences closed the year with outstanding results for 2020, accelerating sales by 58% and initiating the Phase II study for Fibrin PTH, confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds...
News 15.03.2021 Zurich-Schlieren, Switzerland, March 15, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3...
Events, External events
Event date: 15.03.2021
Challenges at the Interface of Formulation, Primary Packaging and Clinical Administration
As pipelines move to progressively challenging biologics, such as bispecific antibodies, fusion proteins and other complex constructs with little to no prior knowledge, a well-designed drug product is essential for addressing the health authorities' expectations and ensuring clinical success.
Are you...